Company news

Revolution Medicines, Inc. news in 2023

Revolution Medicines, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Revolution Medicines Completes Acquisition of EQRx

November 8, 2023

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

November 7, 2023

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

November 5, 2023

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

October 31, 2023

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

October 30, 2023

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

October 21, 2023

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

October 12, 2023

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

October 3, 2023

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

September 18, 2023

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

August 16, 2023

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

August 7, 2023

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

August 2, 2023

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

July 31, 2023

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

May 23, 2023

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

May 7, 2023

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

April 30, 2023

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

April 12, 2023

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

April 5, 2023

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

March 6, 2023

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

March 1, 2023

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

February 26, 2023

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

February 20, 2023

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023